Program Supplement [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

.1).

LbPeB9o19 Prevaleat Study (Premature Vascular Lesions and
Antiretroviral Therapy). A color-Doppler
ultrasonographic comparative study between
patients treated with Pl-including regimens vs
NNRTI-including regimens
Paolo Maggi, Giuseppe Fiorentino, Giuseppe
Epifani, Francesco Perilli, Antonio Lillo, Nicoletta
Ladisa, Sergio Ferraro, Miriam Gargiulo, Antonio
Chirianni, Guido Regina, Giuseppe Pastore (Italy)
LbPeB90o2o Pharmacodynamic effects of zidovudine 6oo mg
once daily versus zidovudine 300 mg twice daily in
therapy-nal've HIV-infected patients (COD20002)
Peter Ruane Gary Richmond, Dejesus Edwin,
Christina Hill-Zabala, Susan Danehower, Qiming
Liao, Judy Johnson, Mark Shaefer (United States)
LbPeB9021 NEKA study: NRTI-sparing regimen
Eugenia Negredo', Anna Bonjoch',
Guillem Sirera', Jordi Puig', Sebastid Videla',
Michel Kurowski2, Xavier Bonafont', Lidia Ruiz',
Bonaventura Clotet' (Spain; 2Germany)
LbPeB9022 Preliminary results of a randomized, controlled
trial of pegylated interferon alpha 2-b with
ribavirin vs interferon alpha 2-b with ribavirin for
treatment of chronic HCV in HIV-1 patients
Josep Mallolas Montse Laguno,
Javier Murillas, Josd M- Sdnchez-Tapias,
Luis Bianchi, Rosa Miquel, Mercedes GarcfaGasalla, Josd Luis Blanco, Esteban Martinez,
Ana Milinkovic, Agata Ledn, Montse Loncd,
Josep Mg Gatell (Spain)
LbPeB9023 Pharmacokinetic (pk) interaction between
lopinavir/ritonavir (LPV/r) and amprenavir (APV)
does not affect virologic response to the
combination of LPV/r, APV and RTV in HIV-infected
patients (pts) with multiple treatment failure
(Puzzle 1-ANRSlo4 Study)
Gilles Raquin Anne-Marie Taburet, Genevieve
Chene, Laurence Morand-Joubert, Cecile Droz,
Isabelle Vincent, Francois Clavel, Pierre-Marie
Girard (France)
LbPeB9024 South African Intrapartum Nevirapine Trial:
selection of resistance mutations
John Sullivan (United States)
LbPeB9025 Strategies to prevent loss of CD4 and onset of
resistance during treatment interruptions
Franco Lori, Renato Maserati', Andrea Foli',
Lina Tomasoni', Marco Migliorino', Franco
Maggiolo', Angelo Pan', Stefania Paolucci',
Carmine Tinelli', Richard D'Aquila2,
Julianna Lisziewicz' (ltaly; 2United States)
LbPeB9o26 Tenofovir DF (TDF) and Didanosine EC (ddl EC):
investigation of pharmacokinetic (PK) drug-drug
and drug-food Interactions
BP Kearney, B Damle, A Plummer, I Sayre,
X Zhang, K Ryan, AK Cheng (United States)
LbPeB9o27 Effects of different first-line HAART regimens on
the content and function of lymphocyte
mitochondria of HIV-infected patients without
lipodystrophy
S Ldpez, 0 Mird, E Martfnez, B Rodrfguez,
A Milinkovic, E Predrol, I Casademont, V Nunes,
I M Gatell, F Cardellach (Spain)

Track C: Epidemiology
LbPeC9028 Telling the truth in microbicide trials: using audio
computer-assisted self-interview (ACASI) to
assess the accuracy of self-reported behavioral
data in a Phase II clinical trial
Abigail Norris Turner', Alana De Kocka, Mohlatlego
Sebola2, Amy Meehan3, Kelly Blanchard2, Anwar
Hoosen2, Nicol Coetzee2, Charlotte Ellertson'
(Mexico; 2South Africa; 3United States)
LbPeC9o29 Prevalence of sexually transmitted diseases and
risk factors in women in a rural area of Southern
Mozambique
Maria Paz Loscertales', Clara Menendez2,
Lloreng Quinto2, Xavier Castellsague2,
Francisco dos Santos', Belen Lloveras2,
Nayana Abarca2, Francesc Xavier Bosch2,
Pedro Luis Alonso2 (Mozambique; 2Spain)
LbPeC9o3o Resurgence of syphilis. Early syphilis among
attenders Sexually Transmitted Infections Units
Montserrat Calmet, Irene Barrabeig, Benicio
Sanz, Pere Armengol, Josep Boronat, Maria Josd
Villena, Mart! Vall, Angela Domifnguez (Spain)
LbPeC9o31 Recruiting gay men into phase Ill HIV vaccine
trials: is it feasible?
Graham Bolding, Lorraine Sherr, Jonathan Elford
(United Kingdom)
LbPeC9o32 Epidemiological surveillance of HIV/AIDS in
Algeria, North Africa Based on the sentinel
sero-surveillance survey
El-Ghalia Fares L Mokhtari (Algeria)
LbPeC9o33 Impact of highly active antiretroviral therapy on
the quality of life of injection drug users
Albert Wu Mahboobeh Safaeian,
Nina Shah, Steffanie Strathdee, David Vlahov,
David Celentano (United States)
LbPeC9o34 First suggestion of a decline in HIV prevalence in
Zimbabwe
Perpetua Kububa, L Dube, S.M. Midzi,
P Nesara, M.E. St. Louis (Zimbabwe)
LbPeC9o35 The main targets in STD control interventions for
HIV prevention in NGOs activities in Nizhny
Novgorod, Russia
Irina Berezhnova Sergey Krivatkin, Svetlana
Seveleva (Russian Federation)
LbPeC9o36 Racial disparities in prevalence and incidence of
H IV infection among young men who have sex
with men: The Baltimore Young Men's Survey
Frangiscos Sifakis, John Hylton, Liza
Solomon, Colin Flynn, Duncan MacKellar, Linda
Valleroy, David Celentano (United States)
LbPeC9o37 What can data on Sexually Transmitted Infections
(STI) from Western Pacific countries tell us about
the HIV Epidemic in the region?
Thuy Nguyen Thi Thanh',
Gilles Poumerol2, Elizabeth Sullivan3
('Philippines; 2Switzerland; 3Australia)

XIV International AIDS Conference BARCELONA - JULY 7-12

17